• Search History (Register)
  • MeSH Browser

Welcome to the international HTA database


Showing [22896 Records] Selected Records [0 Hits] [Clear]
Year Source Title
2009     The Netherlands Organisation for Health Research and Development (ZonMw) [Perioperative strategy in colonic surgery; laparoscopy and/or fast track multimodal management versus standard care]
2021     German Agency for Health Technology Assessment at the German Institute for Medical Documentation and Information (DAHTA DIMDI) [Perioperative antibiotics for prevention of infections in arterial reconstructions with vascular prostheses]
2008     Andalusian Health Technology Assessment Area (AETSA) [Perfusion MR Imaging in differentiating brain gliomas. Meta-analysis and economic assessment]
2008     Andalusian Health Technology Assessment Area (AETSA) [Perfusion MR Imaging in differentiating brain gliomas. Meta-analysis and economic assessment]
2007     The Netherlands Organisation for Health Research and Development (ZonMw) [Performance of specialised breast technicians in diagnostic breast imaging]
2007     The Netherlands Organisation for Health Research and Development (ZonMw) [PERFECT (D): primary care electronic referrals: focus on efficient consultation using telemedicine in dermatology]
2011     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) [Percutaneuous left atrial appendage closure for the prevention of thrombo-embolic events in patients with atrial fibrillation]
2010     The Regional Health Technology Assessment Centre (HTA-centrum) [Percutaneuos transcatheter closure of patent foramen ovale]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Percutaneously implanted interatrial shunt for the treatment of heart failure - Assessment according to §137h Social Code Book V]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Percutaneously implanted interatrial shunt for the treatment of heart failure - Addendum to commission H20-06]
2009     The Netherlands Organisation for Health Research and Development (ZonMw) [Percutaneous vertebroplasty in the treatment of osteoporotic vertebral fractures]
2010     Danish Centre for Evaluation and Health Technology Assessment (DACEHTA) [Percutaneous vertebroplasty as a treatment for osteoporotic vertebral fractures - a health technology assessment]
2011     The Swedish Council on Health Technology Assessment (SBU) [Percutaneous vertebroplasty and balloon kyphoplasty in treating painful osteoporotic vertebral compression fractures]
2013     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) [Percutaneous transluminal septal myocardial ablation (PTSMA) in hypertrophic obstructive cardiomyopathy (HOCM)]
2013     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) [Percutaneous transluminal coronary angioplasty (PTCA) with paclitaxel-coated drug-eluting balloon (DEB). Update 2013]
2016     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) [Percutaneous transluminal coronary angioplasty (PTCA) with drug-eluting balloon (DEB). 2nd Update 2016]
2014     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) [Percutaneous transluminal angioplasty (pta) with drug eluting stents in peripheral arterial disease, upper limb and thorax]
2013     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) [Percutaneous transluminal angioplasty (PTA) of periphery arteries with drug-eluting balloon (DEB)]
2015     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) [Percutaneous transluminal angioplasty (PTA) of peripheral arteries with drug-eluting balloon (DEB)]
2013     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) [Percutaneous transcatheter closure of prosthetic mitral and aortic paravalvular leaks]
2009     Committee for New Health Technology Assessment (CNHTA) [Percutaneous tracheostomy dilator]
2012     Institute for Clinical Effectiveness and Health Policy (IECS) [Percutaneous tibial nerve stimulation for the treatment of overactive bladder]
2021     Agencia de Evaluacion de Tecnologias Sanitarias (AETS) [Percutaneous repair systems for tricuspid valve insufficiency by annuloplasty]
2012     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) [Percutaneous repair of mitral regurgitation with the MitraClip]
2010     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) [Percutaneous repair of mitral regurgitation with the MitraClip]
2009     The Regional Health Technology Assessment Centre (HTA-centrum) [Percutaneous pulmonary valve insertion for patients needing right ventricular outflow reintervention]
2015     Institute for Clinical Effectiveness and Health Policy (IECS) [Percutaneous Mitral Valve Repair System (MitraClip®) for mitral valve insufficiency]
2015     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) [Percutaneous left atrial appendage closure]
2023     Canary Health Service [Percutaneous ethanol injection in thyroid nodular pathology and metastatic cervical adenopathies]
2011     German Agency for Health Technology Assessment at the German Institute for Medical Documentation and Information (DAHTA DIMDI) [Percutaneous coronary intervention with optimal medical therapy vs. optimal medical therapy alone for patients with stable angina pectoris]
2013     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) [Percutaneous coronary intervention for chronic total occlusion]
2009     Committee for New Health Technology Assessment (CNHTA) [Percutaneous cement injection plasty of metastatic bone tumor]
2019     Institute for Clinical Effectiveness and Health Policy (IECS) [Percutaneous cement discoplasty for the treatment of degenerative scoliosis in the elderly]
2011     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) [Percutaneous aortic valve replacement with a side note to hybrid operating rooms]
2010     Institute for Clinical Effectiveness and Health Policy (IECS) [Percutaneous aortic valve replacement for aortic stenosis]
2017     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) [Percutaneous aortic valve replacement (TAVI) in Austria. Part 2: Data analysis]
2010     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) [Percutaneous aortic valve replacement - 2nd Update 2010]
2011     Institute for Clinical Effectiveness and Health Policy (IECS) [Percutaneous acrylic vertebroplasty for the treatment of vertebral fractures]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Perampanel (partial-onset seizures) - Benefit assessment according to §35a Social Code Book V]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Perampanel (generalized epilepsy) - Benefit assessment according to §35a Social Code Book V]
2018     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Perampanel (epilepsy) - Benefit assessment according to §35a Social Code Book (SGB) V]
2012     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Perampanel - Benefit assessment according to § 35a Social Code Book V (dossier assessment)]
2014     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Perampanel - Benefit assessment according to § 35a Social Code Book V (dossier assessment)]
2019     Institute for Clinical Effectiveness and Health Policy (IECS) [Per-oral endoscopic myotomy (POEM) in achalasia]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Penile traction therapy for induratio penis plastica]
2005     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Penile prosthesis implantation in the treatment of erectile dysfunction]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Pemigatinib (cholangiocarcinoma) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V]
2023     Institute for Clinical Effectiveness and Health Policy (IECS) [Pembrolizumab in triple-negative breast cancer]
2022     Institute for Clinical Effectiveness and Health Policy (IECS) [Pembrolizumab in non-small-cell lung cancer]
2022     Institute for Clinical Effectiveness and Health Policy (IECS) [Pembrolizumab for patients with clear-cell renal-cell carcinoma]
2022     Institute for Clinical Effectiveness and Health Policy (IECS) [Pembrolizumab for melanoma treatment in adults]
2022     Institute for Clinical Effectiveness and Health Policy (IECS) [Pembrolizumab for head and neck cancer]
2022     Institute for Clinical Effectiveness and Health Policy (IECS) [Pembrolizumab for advanced or metastatic urothelial carcinoma]
2017     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Pembrolizumab (urothelial carcinoma) - Benefit assessment according to §35a Social Code Book V]
2019     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Pembrolizumab (urothelial carcinoma, first line) - Benefit assessment according to §35a Social Code Book V (new scientific findings)]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Pembrolizumab (urothelial carcinoma first line treatment) - Benefit assessment according to §35a Social Code Book V (expiry of the decision)]
2019     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Pembrolizumab (squamous NSCLC, combination chemotherapy) - Addendum to commission A19-31]
2019     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Pembrolizumab (squamous non-small cell lung cancer) - Benefit assessment according to §35a Social Code Book V]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Pembrolizumab (small bowel cancer) - Benefit assessment according to §35a Social Code Book V]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Pembrolizumab (renal cell carcinoma) - Benefit assessment according to §35a Social Code Book V]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Pembrolizumab (renal cell carcinoma) - Benefit assessment according to § 35a SGB V]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Pembrolizumab (renal cell carcinoma) - Addendum to Commission A22-71]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Pembrolizumab (oesophageal or gastroesophageal junction carcinoma) - Addendum to Commission A21-144]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Pembrolizumab (oesophageal cancer) - Benefit assessment according to §35a Social Code Book V]
2019     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Pembrolizumab (non-squamous NSCLC, combination chemotherapy) - Addendum to commission A19-30]
2019     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Pembrolizumab (non-squamous non-small cell lung cancer) - Benefit assessment according to §35a Social Code Book V]
2016     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Pembrolizumab (non-small cell lung cancer) - Benefit assessment according to §35a Social Code Book V]
2017     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Pembrolizumab (non-small cell lung cancer) - Benefit assessment according to §35a Social Code Book V]
2017     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Pembrolizumab (non-small cell lung cancer) - Addendum to Commission A17-06]
2019     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Pembrolizumab (melanoma) - Benefit assessment according to §35a Social Code Book V]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Pembrolizumab (melanoma, advanced) - Benefit assessment according to § 35a SGB V]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Pembrolizumab (melanoma, adjuvant) - Benefit assessment according to § 35a SGB V]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Pembrolizumab (Hodgkin lymphoma) - Benefit assessment according to §35a Social Code Book V]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Pembrolizumab (Hodgkin lymphoma) - Addendum to Commission A21-35]
2019     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Pembrolizumab (head and neck squamous cell carcinoma) - Benefit assessment according to §35a Social Code Book V]
2020     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Pembrolizumab (head and neck squamous cell carcinoma, monotherapy) - Benefit assessment according to §35a Social Code Book V]
2020     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Pembrolizumab (head and neck squamous cell carcinoma, combination therapy) - Benefit assessment according to §35a Social Code Book V]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Pembrolizumab (gastric or gastro-oesophageal junction adenocarcinoma, HER2-positive) – Benefit assessment according to §35a Social Code Book V]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Pembrolizumab (gastric cancer) - Benefit assessment according to §35a Social Code Book V]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Pembrolizumab (gastric cancer, HER2-negative) – Benefit assessment according to §35a Social Code Book V]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Pembrolizumab (endometrial carcinoma) - Benefit assessment according to §35a Social Code Book V]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Pembrolizumab (endometrial carcinoma) - Addendum to Commission A21-164]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Pembrolizumab (endometrial cancer) - Benefit assessment according to §35a Social Code Book V]
2020     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Pembrolizumab (combination with axitinib, renal cell carcinoma) - Benefit assessment according to §35a Social Code Book V]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Pembrolizumab (colorectal cancer) - Benefit assessment according to §35a Social Code Book V]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Pembrolizumab (colorectal cancer) - Benefit assessment according to § 35a SGB V]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Pembrolizumab (colorectal cancer) - Addendum to Commission A21-36]
2017     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Pembrolizumab (classical Hodgkin lymphoma) - Benefit assessment according to §35a Social Code Book V]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Pembrolizumab (cervical cancer) - Benefit assessment according to § 35a SGB V]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Pembrolizumab (cervical cancer) - Addendum to Commission A22-70]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Pembrolizumab (breast cancer) - Benefit assessment according to § 35a Social Code Book V]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Pembrolizumab (breast cancer) - Addendum to Commission A22-63]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Pembrolizumab (breast cancer, triple-negative, locally recurrent/metastatic, in combination with chemotherapy) - Benefit assessment according to §35a Social Code Book V]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Pembrolizumab (breast cancer, triple-negative, locally recurrent/metastatic, in combination with chemotherapy) - Benefit assessment according to §35a Social Code Book V]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Pembrolizumab (biliary cancer) – Benefit assessment according to §35a Social Code Book V]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Pembrolizumab (bile cancer) - Benefit assessment according to § 35a SGB V]
2015     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Pembrolizumab - Benefit assessment according to §35a Social Code Book V (dossier assessment)]
2016     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Pembrolizumab - Addendum to Commission A15-33]
2019     Institute for Clinical Effectiveness and Health Policy (IECS) [Pelvic vein embolization or sclerotherapy in pelvic congestion syndrome]
2017     Institute for Clinical Effectiveness and Health Policy (IECS) [Pelvic vein embolization or sclerotherapy in pelvic congestion syndrome]